Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 gp41 membrane-proximal external region (MPER) is a highly conserved, tryptophan-rich sequence located at the C-terminal end of the gp41 ectodomain, immediately preceding the transmembrane domain (Montero et al., 2008, PMID: 18772287). During HIV-1 entry, the envelope glycoprotein complex (gp120/gp41) undergoes conformational changes upon binding to CD4 and coreceptors, leading to the formation of a transient pre-hairpin intermediate where the MPER is exposed (Frey et al., 2008, PMID: 18332424). This intermediate state is a critical target for broadly neutralizing antibodies (bNAbs) such as 2F5, 4E10, and 10E8, which bind to the MPER and block the transition to the post-fusion six-helix bundle, thereby preventing viral-cell membrane fusion (Huang et al., 2012, PMID: 23151583). Because the MPER is essential for the fusion process and is highly conserved across diverse HIV-1 strains, it is a primary focus for vaccine design and the development of fusion-inhibitor drugs (Kim et al., 2014, PMID: 24501411). However, therapeutic targeting is complicated by the MPER's close proximity to the viral lipid bilayer and its limited accessibility during the short-lived pre-hairpin stage (Ofek et al., 2004, PMID: 15548732).
Inhibition of viral-cell membrane fusion by binding to the transiently exposed pre-hairpin intermediate of gp41, preventing the formation of the six-helix bundle (Zhu et al., 2013, PMID: 23596311).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER) (HIV-1 gp41 MPER).